培哚普利联合冻干重组人脑利钠肽治疗难治性心力衰竭对照观察

Comparison of perindopril combined with freeze-dried recombinant human brain natriuretic peptide in the treatment of refractory heart failure

目的探讨培哚普利联合冻干重组人脑利钠肽治疗难治性心力衰竭的临床疗效及对患者血清氨基末端脑利钠肽前体、C反应蛋白水平的影响.方法将74例难治性心力衰竭患者按随机数字表法分为两组,各37例.对照组予以培哚普利治疗,观察组予以培哚普利联合冻干重组人脑利钠肽治疗,观察8周.比较两组临床疗效及治疗前后心功能(左心室舒张末期内径、左心室射血分数)、血清氨基末端脑利钠肽前体、C反应蛋白水平.结果观察组总有效率为91.9%,对照组为73.0%,观察组显著高于对照组(P<0.05).治疗后两组左心室舒张末期内径及血清氨基末端脑利钠肽前体、C反应蛋白水平均较治疗前显著降低(P<0.01),左心室射血分数较治疗前显著升高(P<0.01),观察组显著优于对照组(P<0.01).结论培哚普利联合冻干重组人脑利钠肽治疗难治性心力衰竭,可显著降低患者血清氨基末端脑利钠肽前体、C反应蛋白水平,有效促进患者心功能恢复,临床疗效显著.

Objective To investigate the clinical efficacy of perindopril combined with freeze-dried recombinant human brain natriuretic peptide in the treatment of refractory heart failure and its effect on serum NTproBNP and CRP levels.Methods 74 patients with refractory heart failure were divided into two groups according to the random number table,37 cases each.The control group was treated with perindopril,and the observation group was treated with perindopril combined with lyophilized recombinant human brain natriuretic peptide for 8 weeks.The clinical efficacy and cardiac function(LVEDD,LVEF),serum NTproBNP and CRP levels were compared between the two groups.Results The total effective rate was 91.9% in the observation group and 73.0% in the control group.The observation group was significantly higher than the control group(P<0.05).After treatment,the levels of LVEDD and serum NT-proBNP and CRP levels were significantly lower than those before treatment(P<0.01),and LVEF was significantly higher than before treatment(P<0.01).The observation group was significantly better than the control group(P<0.01).Conclusions Perindopril combined with freeze-dried recombinant human brain natriuretic peptide for the treatment of refractory heart failure can significantly reduce the levels of serum NT-proBNP and CRP,and effectively promote the recovery of cardiac function in patients,clinical efficacy is significant.